KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions
KALV Stock Forecast
KalVista Pharmaceuticals stock forecast is as follows: an average price target of $22.67 (represents a 171.17% upside from KALV’s last price of $8.36) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KALV Price Target
The average price target for KalVista Pharmaceuticals (KALV) is $22.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $20.00. This represents a potential 171.17% upside from KALV's last price of $8.36.
KALV Analyst Ratings
According to 4 Wall Street analysts, KalVista Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KALV stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
KalVista Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Serge Belanger | Needham | $28.00 | $11.25 | 148.89% | 234.93% |
| Sep 06, 2024 | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | 55.40% | 139.23% |
| Sep 06, 2024 | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | 55.40% | 139.23% |
| Jul 08, 2022 | Needham | $38.00 | $10.98 | 246.08% | 354.55% |
The latest KalVista Pharmaceuticals stock forecast, released on Nov 05, 2024 by Serge Belanger from Needham, set a price target of $28.00, which represents a 148.89% increase from the stock price at the time of the forecast ($11.25), and a 234.93% increase from KALV last price ($8.36).
KalVista Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $28.00 | $22.67 |
| Last Closing Price | $8.36 | $8.36 | $8.36 |
| Upside/Downside | -100.00% | 234.93% | 171.17% |
In the current month, the average price target of KalVista Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to KalVista Pharmaceuticals's last price of $8.36. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Feb 03, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | Needham | Buy | Buy | Hold |
KalVista Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave KALV a "Buy" rating, the same as its previous rate.
KalVista Pharmaceuticals Financial Forecast
KalVista Pharmaceuticals Revenue Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.58M | $3.92M | $3.37M | - | $3.89M | - | $1.13M | - | - |
| Avg Forecast | $24.56M | $16.73M | $11.69M | $1.65M | $3.95M | $1.97M | $518.00K | - | $4.46M | $420.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $618.16K | $115.69K | $7.40K | $266.76K |
| High Forecast | $24.56M | $16.73M | $11.69M | $1.65M | $3.95M | $1.97M | $518.00K | - | $4.46M | $504.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $741.79K | $138.82K | $8.88K | $320.12K |
| Low Forecast | $24.56M | $16.73M | $11.69M | $1.65M | $3.95M | $1.97M | $518.00K | - | $4.46M | $336.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $494.53K | $92.55K | $5.92K | $213.41K |
| # Analysts | 2 | 2 | 1 | 1 | 4 | 1 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.16% | 1.20% | 1.05% | - | 0.91% | - | 9.74% | - | - |
KalVista Pharmaceuticals's average Quarter revenue forecast for May 20 based on 12 analysts is $1.90M, with a low forecast of $1.90M, and a high forecast of $1.90M. KALV's average Quarter revenue forecast represents a 20.21% increase compared to the company's last Quarter revenue of $1.58M (Jan 20).
KalVista Pharmaceuticals EBITDA Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 1 | 1 | 4 | 1 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-12.82M | $-12.62M | $-14.75M | - | $-12.58M | $-9.59M | $-8.85M | - | $-6.80M | - | $-5.97M | - | - |
| Avg Forecast | $4.91M | $3.35M | $2.34M | $330.00K | $789.20K | $394.60K | $103.60K | - | $892.05K | $-13.87M | $240.00K | $125.00K | $300.00K | $-9.91M | $2.02M | $653.23K | $644.20K | $-5.16M | $850.60K | $-8.25M | $-5.56M | $-4.21M | $-164.52M |
| High Forecast | $4.91M | $3.35M | $2.34M | $330.00K | $789.20K | $394.60K | $103.60K | - | $892.05K | $-11.10M | $240.00K | $125.00K | $300.00K | $-7.93M | $2.02M | $653.23K | $644.20K | $-4.13M | $850.60K | $-6.60M | $-4.45M | $-3.37M | $-131.61M |
| Low Forecast | $4.91M | $3.35M | $2.34M | $330.00K | $789.20K | $394.60K | $103.60K | - | $892.05K | $-16.65M | $240.00K | $125.00K | $300.00K | $-11.90M | $2.02M | $653.23K | $644.20K | $-6.20M | $850.60K | $-9.91M | $-6.67M | $-5.05M | $-197.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -53.43% | -100.99% | -49.18% | - | -6.24% | -14.68% | -13.74% | - | -8.00% | - | 1.07% | - | - |
undefined analysts predict KALV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than KalVista Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
KalVista Pharmaceuticals Net Income Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 1 | 1 | 4 | 1 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-10.05M | $-10.43M | $-10.81M | - | $-9.29M | $-5.90M | $-7.34M | - | $-3.96M | - | $-4.99M | - | - |
| Avg Forecast | $-24.05M | $-28.25M | $-30.82M | $-36.89M | $-41.96M | $-40.76M | $-42.40M | $-42.30M | $-33.28M | $-10.87M | $-27.54M | $-31.04M | $-27.66M | $-10.22M | $-12.09M | $-25.43M | $-28.51M | $-5.30M | $-20.71M | $-8.33M | $-5.60M | $-4.29M | $-197.56M |
| High Forecast | $-24.05M | $-28.25M | $-30.82M | $-36.89M | $-41.96M | $-35.12M | $-41.94M | $1.05M | $-33.28M | $-8.70M | $-27.54M | $-31.04M | $-27.66M | $-8.18M | $-12.09M | $-25.43M | $-28.51M | $-4.24M | $-20.71M | $-6.67M | $-4.48M | $-3.43M | $-158.05M |
| Low Forecast | $-24.05M | $-28.25M | $-30.82M | $-36.89M | $-41.96M | $-46.39M | $-43.32M | $-85.65M | $-33.28M | $-13.05M | $-27.54M | $-31.04M | $-27.66M | $-12.26M | $-12.09M | $-25.43M | $-28.51M | $-6.36M | $-20.71M | $-10.00M | $-6.72M | $-5.14M | $-237.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.36% | 0.34% | 0.39% | - | 0.77% | 0.23% | 0.26% | - | 0.19% | - | 0.89% | - | - |
KalVista Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KALV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
KalVista Pharmaceuticals SG&A Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 1 | 1 | 4 | 1 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.56M | $3.63M | $3.28M | - | $3.07M | $3.42M | $3.25M | - | $2.90M | - | $2.70M | - | - |
| Avg Forecast | $26.22M | $17.86M | $12.47M | $1.76M | $4.21M | $2.11M | $552.99K | - | $4.76M | $448.37K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $3.89M | $4.54M | $659.92K | $123.50K | $7.90K | $284.78K |
| High Forecast | $26.22M | $17.86M | $12.47M | $1.76M | $4.21M | $2.11M | $552.99K | - | $4.76M | $538.04K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $4.66M | $4.54M | $791.90K | $148.20K | $9.48K | $341.74K |
| Low Forecast | $26.22M | $17.86M | $12.47M | $1.76M | $4.21M | $2.11M | $552.99K | - | $4.76M | $358.70K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $3.11M | $4.54M | $527.93K | $98.80K | $6.32K | $227.82K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 2.78% | 5.44% | 2.05% | - | 0.29% | 0.98% | 0.94% | - | 0.64% | - | 21.89% | - | - |
KalVista Pharmaceuticals's average Quarter SG&A projection for May 21 is $448.37K, based on 14 Wall Street analysts, with a range of $358.70K to $538.04K. The forecast indicates a -87.41% fall compared to KALV last annual SG&A of $3.56M (Jan 21).
KalVista Pharmaceuticals EPS Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 1 | 1 | 4 | 1 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.39 | $-0.44 | $-0.36 | - | $-0.30 | $-0.11 | $-0.32 | - | $-0.06 | - | $-0.40 | - | - |
| Avg Forecast | $-0.52 | $-0.60 | $-0.66 | $-0.79 | $-0.90 | $-0.87 | $-0.91 | $-0.92 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.21 | $-0.67 | $-1.68 | $-88.79 |
| High Forecast | $-0.52 | $-0.60 | $-0.66 | $-0.79 | $-0.90 | $-0.75 | $-0.90 | $0.02 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.17 | $-0.54 | $-1.34 | $-71.04 |
| Low Forecast | $-0.52 | $-0.60 | $-0.66 | $-0.79 | $-0.90 | $-0.99 | $-0.93 | $-1.85 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.25 | $-0.80 | $-2.02 | $-106.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.66% | 0.60% | - | 1.15% | 0.20% | 0.52% | - | 0.13% | - | 0.60% | - | - |
According to undefined Wall Street analysts, KalVista Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KALV previous annual EPS of $NaN (undefined).
KalVista Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| KALV | KalVista Pharmaceuticals | $8.65 | $22.67 | 162.08% | Buy |
| KURA | Kura Oncology | $9.74 | $23.33 | 139.53% | Buy |
| IMCR | Immunocore | $29.40 | $70.20 | 138.78% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| COGT | Cogent Biosciences | $8.19 | $16.00 | 95.36% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| DYN | Dyne Therapeutics | $26.16 | $49.00 | 87.31% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| MRSN | Mersana Therapeutics | $2.03 | $3.00 | 47.78% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.65 | $57.00 | 33.65% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| VRDN | Viridian Therapeutics | $20.82 | $22.75 | 9.27% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |